• Company
• ‘Lilly will reapply for Retevmo’s reimbursement in Korea’
• by Eo, Yun-Ho Aug 26, 2024 05:46am

• Company
• Colorectal cancer drug Fruzaqla may be introduced in H2
• by Eo, Yun-Ho Aug 26, 2024 05:46am

• Company
• Expansion of newly launched Kerendia underway in KOR
• by Moon, sung-ho Aug 23, 2024 06:18am

• Company
• Will the SGLT-2i Jardiance be reimb for CKD in 2H?
• by Eo, Yun-Ho Aug 23, 2024 06:18am

• Company
• Yungjin applies for approval of its Ofev generic
• by Hwang, Byung-woo Aug 23, 2024 06:17am

• Company
• Yuhan’s Leclaza enters US 6yrs after signing licensing deal
• by Chon, Seung-Hyun Aug 22, 2024 05:50am

• Company
• Bavencio shows clear benefit in urothelial cancer
• by Hwang, Byung-woo Aug 22, 2024 05:50am

• Company
• MET-targeting anticancer drug 'Tepmetko' prescribed at Big 5
• by Eo, Yun-Ho Aug 22, 2024 05:50am

• Company
• SCLC drug tarlatamab may soon be introduced in KOR
• by Eo, Yun-Ho Aug 21, 2024 05:48am

• Company
• Celltrion Pharm announces vision to become ‘Top 5'
• by Kim, Jin-Gu Aug 20, 2024 06:34am